At-a-Glance

COVID-19 Vaccination Schedule for Most People
(People who are NOT Moderately or Severely Immunocompromised)

People ages 6 months through 4 years

- Moderna
  - Primary In 4-8 weeks
  - Primary
- Pfizer-BioNTech
  - Primary
  - In at least 8 weeks

People ages 5 through 11 years

- Moderna
  - Primary In 4-8 weeks
  - Primary
- Pfizer-BioNTech
  - Primary In at least 5 months
  - Monovalent Booster

People ages 12 years and older

- Moderna, Novavax, or Pfizer-BioNTech
  - Primary In 3-8 weeks (Novavax, Pfizer)
  - Primary In at least 2 months
  - Bivalent booster*

People ages 18 years and older who previously received Janssen primary series dose†

- Primary In at least 2 months
  - Bivalent booster*

Note: This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

- The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

† Janssen COVID-19 Vaccine should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a
COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

People ages 6 months through 4 years

Modern

In 3 weeks

-OR-

Pfizer-BioNTech

In at least 8 weeks

In at least 3 months

Monovalent Booster

People ages 5 years through 11 years

Modern

In 4 weeks

In at least 4 weeks

Pfizer-BioNTech

In 3 weeks

In at least 4 weeks

For more specific clinical guidance, see:

- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
At-a-Glance

COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

People ages 12 years and older

Modern or Pfizer-BioNTech

Primary → Primary → Primary → Bivalent booster*

-OR-

Novavax

Primary → Primary → Primary → Bivalent booster*

People ages 18 years and older who previously received Janssen primary series dose†

Primary → Addl mRNA dose → Bivalent booster*

Monoclonal antibodies (EVUSHELD™) for COVID-19 pre-exposure prophylaxis

People ages 12 years and older (must weigh at least 40kg)

Any dose (primary or booster) → EVUSHELD™ dose every 6 months → Any subsequent COVID-19 vaccine dose

For more specific clinical guidance, see:
- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Note: This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

- The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

† Janssen COVID-19 Vaccine should only be used in certain limited situations. See: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a